GlassScriptPhysician profile
Richard J Hauser
NPI 1558358333
$3,083.68
in general payments reported to CMS, 2019-2025
41 companies · $306 in 2025
The $306 reported for 2025 was more than what a typical Primary Podiatric Medicine provider received nationally (typical 2025 total: $232).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $976 · 2020: $691 · 2021: $52.28 · 2022: $122 · 2023: $400 · 2024: $536 · 2025: $306.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,242.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,241.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $347.77 | 2019-2025 | Apligraf, Puraply |
| Musculoskeletal Transplant Foundation INC. | $303.30 | 2019-2020 | |
| Smith+Nephew, INC. | $260.90 | 2019-2025 | Grafix Pl, Stravix |
| Zimmer Biomet Holdings, INC. | $198.76 | 2019-2020 | |
| Nevro Corp. | $162.16 | 2024 | Senza |
| Amgen INC. | $156.27 | 2024-2025 | Krystexxa |
| Convatec INC. | $151.98 | 2023 | |
| Amniox Medical, INC. | $137.17 | 2019 | |
| Osiris Therapeutics INC. | $136.23 | 2019 | |
| In2bones USA, LLC | $134.24 | 2019 | |
| Kerecis Limited | $127.89 | 2020 | |
| Tei Medical INC. | $83.97 | 2019 | |
| Paratek Pharmaceuticals, INC. | $83.32 | 2023-2025 | Nuzyra |
| Djo, LLC | $77.13 | 2019 | |
| Biowound Solutions, INC. | $69.64 | 2025 | Bio-Connekt |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $56.25 | 2022-2023 | Intellis Adaptivestim |
| Abbott Laboratories | $45.93 | 2023-2024 | Proclaim |
| Epsfl, LLC | $45.36 | 2023 | |
| Osteocentric Technologies, INC. | $37.85 | 2019 | |
| Acell, INC. | $34.35 | 2019 | |
| Bioventus LLC | $31.31 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $28.91 | 2024 | |
| Integra Lifesciences Corporation | $28.29 | 2024 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Bsn Medical INC | $24.81 | 2023 | |
| Triad Life Sciences INC. | $24.41 | 2022 | |
| Boston Scientific Corporation | $24.38 | 2024 | |
| Next Science LLC | $24.25 | 2023 | Xperience, Blastx, Surgx |
| Grt US Holding, INC. | $24.25 | 2022 | |
| Stryker Corporation | $23.57 | 2024 | 1788 |
| Fidia Pharma USA INC. | $23.55 | 2021 | |
| Lifenet Health | $23.34 | 2025 | Theragenesis Wound Matrix |
| Wright Medical Technology, INC. | $19.70 | 2020 | |
| Normatec Industries, LP | $17.80 | 2019 | |
| Merck Sharp & Dohme LLC | $16.61 | 2019 | |
| Medtronic Vascular, INC. | $16.15 | 2019 | |
| Treace Medical Concepts, INC. | $15.52 | 2022 | |
| Solventum Corporation | $15.47 | 2025 | Promogran Prisma |
| Medela LLC | $13.67 | 2019 | |
| Polarityte, INC. | $13.46 | 2019 | |
| Zyla Life Sciences, INC. | $12.67 | 2019 | |
| Depuy Synthes Sales INC. | $11.09 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Hauser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.